- Home
- SFWL vs GNTA Comparison
SFWL vs GNTA Comparison
Compare SFWL & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- GNTA
- Stock Information
- Founded
- SFWL 2001
- GNTA 2014
- Country
- SFWL China
- GNTA Italy
- Employees
- SFWL N/A
- GNTA N/A
- Industry
- SFWL Trucking Freight/Courier Services
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SFWL Industrials
- GNTA Health Care
- Exchange
- SFWL Nasdaq
- GNTA Nasdaq
- Market Cap
- SFWL 82.3M
- GNTA 70.6M
- IPO Year
- SFWL 2023
- GNTA 2021
- Fundamental
- Price
- SFWL $1.03
- GNTA $3.51
- Analyst Decision
- SFWL
- GNTA Strong Buy
- Analyst Count
- SFWL 0
- GNTA 1
- Target Price
- SFWL N/A
- GNTA $25.00
- AVG Volume (30 Days)
- SFWL 16.6K
- GNTA 5.0K
- Earning Date
- SFWL 09-04-2025
- GNTA 01-01-0001
- Dividend Yield
- SFWL N/A
- GNTA N/A
- EPS Growth
- SFWL 4.79
- GNTA N/A
- EPS
- SFWL 0.13
- GNTA N/A
- Revenue
- SFWL $504,158,000.00
- GNTA N/A
- Revenue This Year
- SFWL N/A
- GNTA N/A
- Revenue Next Year
- SFWL N/A
- GNTA N/A
- P/E Ratio
- SFWL $7.88
- GNTA N/A
- Revenue Growth
- SFWL 24.75
- GNTA N/A
- 52 Week Low
- SFWL $0.86
- GNTA $2.74
- 52 Week High
- SFWL $1.60
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- SFWL 53.17
- GNTA 46.17
- Support Level
- SFWL $1.05
- GNTA $3.23
- Resistance Level
- SFWL $1.07
- GNTA $3.75
- Average True Range (ATR)
- SFWL 0.05
- GNTA 0.25
- MACD
- SFWL -0.00
- GNTA 0.00
- Stochastic Oscillator
- SFWL 17.65
- GNTA 60.81
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.